Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PINBOT
2022-500727-68-01Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in diabetic neuropathy and diabetic polyneuropathy (DPN) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Pain relief (NRS) over 24 weeks. Planned start Nov 2022; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
diabetic neuropathydiabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2022-500727-68-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500727-68-01.